VX-147

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Kidney DiseaseFocal Segmental Glomerulosclerosis

245 competitors in Kidney Disease

#DrugCompanyPhaseTrials

1

Invirase

Roche

Phase 3

12

Edarbi

Takeda

Phase 3

13

Evrenzo

Astellas

Phase 3

14

Zemplar

AbbVie

Phase 3

15

Reata

Biogen

Phase 3

16

Victoza

Novo Nordisk

Phase 3

17

Myfortic

Novartis

Phase 3

—8

Aranesp

Amgen

Phase 3

—9

Gazyva

Roche

Phase 3

—10

Rituxan

Roche

Phase 3

—Show 27 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Focal Segmental Glomerulosclerosis1 trial

Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis

Completed·Vertex Pharmaceuticals·Phase 2·NCT04340362·16 enrolled

Proteinuric Kidney Disease1 trial

A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease

Recruiting·Vertex Pharmaceuticals·Preclinical·NCT05312879·466 enrolled

Unspecified1 trial

A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147

Completed·Vertex Pharmaceuticals·Phase 1·NCT05955872·21 enrolled

Details

Drug Info

Related News